Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ammoxetine in Depression (Phase 2)
NCT05018013Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ammoxetine in major depressive disorder (MDD), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05018013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018013.